Steven Cohen’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-893,295
| Closed | -$18.7M | – | 4482 |
|
|
2026
Q1 | $18.7M | Buy |
+893,295
| New | +$20.1M | 0.02% | 834 |
|
|
2025
Q3 | – | Sell |
-515,968
| Closed | -$18.8M | – | 2618 |
|
|
2025
Q2 | $18.8M | Sell |
515,968
-460,084
| -47% | -$16.6M | 0.04% | 527 |
|
|
2025
Q1 | $35.3M | Sell |
976,052
-206,825
| -17% | -$8.6M | 0.08% | 298 |
|
|
2024
Q4 | $49.8M | Buy |
1,182,877
+529,217
| +81% | +$26.3M | 0.11% | 218 |
|
|
2024
Q3 | $36.3M | Buy |
653,660
+113,911
| +21% | +$5.8M | 0.09% | 258 |
|
|
2024
Q2 | $22.2M | Buy |
539,749
+478,849
| +786% | +$20.4M | 0.06% | 375 |
|
|
2024
Q1 | $2.84M | Sell |
60,900
-41,600
| -41% | -$1.96M | 0.01% | 1153 |
|
|
2023
Q4 | $4.9M | Sell |
102,500
-613,962
| -86% | -$23.8M | 0.01% | 931 |
|
|
2023
Q3 | $25.5M | Buy |
716,462
+291,588
| +69% | +$11.6M | 0.07% | 337 |
|
|
2023
Q2 | $19.6M | Sell |
424,874
-961,987
| -69% | -$44.6M | 0.06% | 390 |
|
|
2023
Q1 | $55.6M | Buy |
1,386,861
+659,174
| +91% | +$28.3M | 0.17% | 150 |
|
|
2022
Q4 | $33.7M | Buy |
727,687
+377,000
| +108% | +$14.8M | 0.11% | 231 |
|
|
2022
Q3 | $14.5M | Buy |
350,687
+77,172
| +28% | +$3.97M | 0.06% | 410 |
|
|
2022
Q2 | $16.3M | Sell |
273,515
-44,982
| -14% | -$2.77M | 0.07% | 368 |
|
|
2022
Q1 | $23.1M | Sell |
318,497
-107,377
| -25% | -$7.47M | 0.09% | 292 |
|
|
2021
Q4 | $35.8M | Buy |
425,874
+85,500
| +25% | +$6.96M | 0.14% | 196 |
|
|
2021
Q3 | $30.7M | Sell |
340,374
-366,926
| -52% | -$33.2M | 0.13% | 204 |
|
|
2021
Q2 | $67.4M | Buy |
707,300
+587,700
| +491% | +$61.2M | 0.3% | 74 |
|
|
2021
Q1 | $13.6M | Sell |
119,600
-100
| -0.1% | -$13.6K | 0.06% | 353 |
|
|
2020
Q4 | $16.6M | Buy |
+119,700
| New | +$14.2M | 0.08% | 321 |
|
|
2020
Q1 | – | Sell |
-117,496
| Closed | -$5.02M | – | 1031 |
|
|
2019
Q4 | $5.02M | Buy |
117,496
+61,680
| +111% | +$2.54M | 0.03% | 497 |
|
|
2019
Q3 | $2.39M | Buy |
55,816
+21,553
| +63% | +$1.17M | 0.01% | 571 |
|
|
2019
Q2 | $2.18M | Buy |
+34,263
| New | +$2.18M | 0.01% | 641 |
|
|
2019
Q1 | – | Sell |
-173,700
| Closed | -$7.55M | – | 1193 |
|
|
2018
Q4 | $7.55M | Buy |
173,700
+138,700
| +396% | +$7.58M | 0.04% | 460 |
|
|
2018
Q3 | $2.67M | Sell |
35,000
-25,000
| -42% | -$2.03M | 0.01% | 717 |
|
|
2018
Q2 | $4.61M | Sell |
60,000
-10,000
| -14% | -$646K | 0.02% | 626 |
|
|
2018
Q1 | $3.57M | Sell |
70,000
-23,400
| -25% | -$1.18M | 0.01% | 646 |
|
|
2017
Q4 | $4.33M | Buy |
93,400
+43,400
| +87% | +$2.13M | 0.02% | 623 |
|
|
2017
Q3 | $2.66M | Sell |
50,000
-15,000
| -23% | -$889K | 0.01% | 638 |
|
|
2017
Q2 | $4.04M | Sell |
65,000
-15,000
| -19% | -$904K | 0.02% | 546 |
|
|
2017
Q1 | $5.42M | Buy |
+80,000
| New | +$6.1M | 0.03% | 512 |
|
Other funds holding RARE
RI
FCM
Steven Cohen's RARE Position: Q2 2026 in Review
Steven Cohen sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 893,295 shares — an estimated $18.7M sold.
Steven Cohen first reported a position in RARE in Q1 2017 and held it in 31 quarters. The position peaked at $67.4M in Q2 2021. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Steven Cohen reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
- Steven Cohen sold 893,295 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $18.7M.
- Steven Cohen first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and held it in 31 quarters.
- Steven Cohen's Ultragenyx Pharmaceutical position peaked at $67.4M in Q2 2021.
- 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.